The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition

Molecular Cell

Volumn 54, Issue 5, 2014, Pages 728-736

  Shi, Junwei ^a,b   Vakoc, Christopher R ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BRD4 PROTEIN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BRD2 PROTEIN, HUMAN; BRD3 PROTEIN, HUMAN; BRD4 PROTEIN, HUMAN; BRDT PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BROMODOMAIN; COMPLEX FORMATION; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; MOLECULAR MECHANICS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS;

EID: 84901821841     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2014.05.016     Document Type: Review

References (78)

1. Adelman K., Lis J.T. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat. Rev. Genet. 2012, 13:720-731.
2. Anand P., Brown J.D., Lin C.Y., Qi J., Zhang R., Artero P.C., Alaiti M.A., Bullard J., Alazem K., Margulies K.B., et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell 2013, 154:569-582.
3. Anders L., Guenther M.G., Qi J., Fan Z.P., Marineau J.J., Rahl P.B., Lovén J., Sigova A.A., Smith W.B., Lee T.I., et al. Genome-wide localization of small molecules. Nat. Biotechnol. 2014, 32:92-96.
4. Bandukwala H.S., Gagnon J., Togher S., Greenbaum J.A., Lamperti E.D., Parr N.J., Molesworth A.M., Smithers N., Lee K., Witherington J., et al. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc. Natl. Acad. Sci. USA 2012, 109:14532-14537.
5. Banerjee C., Archin N., Michaels D., Belkina A.C., Denis G.V., Bradner J., Sebastiani P., Margolis D.M., Montano M. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J.Leukoc. Biol. 2012, 92:1147-1154.
6. Bartholomeeusen K., Xiang Y., Fujinaga K., Peterlin B.M. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b(P-TEFb) from 7SK small nuclear ribonucleoprotein. J.Biol. Chem. 2012, 287:36609-36616.
7. Belkina A.C., Nikolajczyk B.S., Denis G.V. BET protein function isrequired for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J.Immunol. 2013, 190:3670-3678.
8. Bisgrove D.A., Mahmoudi T., Henklein P., Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc. Natl. Acad. Sci. USA 2007, 104:13690-13695.
9. Boehm D., Calvanese V., Dar R.D., Xing S., Schroeder S., Martins L., Aull K., Li P.C., Planelles V., Bradner J.E., et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 2013, 12:452-462.
10. Calo E., Wysocka J. Modification of enhancer chromatin: what, how, and why?. Mol. Cell 2013, 49:825-837.
11. Chapuy B., McKeown M.R., Lin C.Y., Monti S., Roemer M.G., Qi J., Rahl P.B., Sun H.H., Yeda K.T., Doench J.G., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.
12. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
13. Dawson M.A., Gudgin E.J., Horton S.J., Giotopoulos G., Meduri E., Robson S., Cannizzaro E., Osaki H., Wiese M., Putwain S., et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 2014, 28:311-320.
14. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
15. Devaiah B.N., Lewis B.A., Cherman N., Hewitt M.C., Albrecht B.K., Robey P.G., Ozato K., Sims R.J., Singer D.S. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc. Natl. Acad. Sci. USA 2012, 109:6927-6932.
16. Dey A., Chitsaz F., Abbasi A., Misteli T., Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. USA 2003, 100:8758-8763.
17. Dey A., Nishiyama A., Karpova T., McNally J., Ozato K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol. Biol. Cell 2009, 20:4899-4909.
18. Dhalluin C., Carlson J.E., Zeng L., He C., Aggarwal A.K., Zhou M.M. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999, 399:491-496.
19. Donner A.J., Ebmeier C.C., Taatjes D.J., Espinosa J.M. CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat. Struct. Mol. Biol. 2010, 17:194-201.
20. Filippakopoulos P., Knapp S. The bromodomain interaction module. FEBS Lett. 2012, 586:2692-2704.
21. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
22. Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., Barsyte-Lovejoy D., Felletar I., Volkmer R., Müller S., Pawson T., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012, 149:214-231.
23. Floyd S.R., Pacold M.E., Huang Q., Clarke S.M., Lam F.C., Cannell I.G., Bryson B.D., Rameseder J., Lee M.J., Blake E.J., et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature 2013, 498:246-250.
24. French C.A. Pathogenesis of NUT midline carcinoma. Annu. Rev. Pathol. 2012, 7:247-265.
25. Gamsjaeger R., Webb S.R., Lamonica J.M., Billin A., Blobel G.A., Mackay J.P. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol. Cell. Biol. 2011, 31:2632-2640.
26. Greenwald R.J., Tumang J.R., Sinha A., Currier N., Cardiff R.D., Rothstein T.L., Faller D.V., Denis G.V. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 2004, 103:1475-1484.
27. Gröschel S., Sanders M.A., Hoogenboezem R., de Wit E., Bouwman B.A., Erpelinck C., van der Velden V.H., Havermans M., Avellino R., van Lom K., et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 2014, 157:369-381.
28. Hargreaves D.C., Horng T., Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 2009, 138:129-145.
29. Hayden M.S., Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26:203-234.
30. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-André V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
31. Huang B., Yang X.D., Zhou M.M., Ozato K., Chen L.F. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol. Cell. Biol. 2009, 29:1375-1387.
32. Jang M.K., Mochizuki K., Zhou M., Jeong H.S., Brady J.N., Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19:523-534.
33. Jeronimo C., Forget D., Bouchard A., Li Q., Chua G., Poitras C., Thérien C., Bergeron D., Bourassa S., Greenblatt J., et al. Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme. Mol. Cell 2007, 27:262-274.
34. Jiang Y.W., Veschambre P., Erdjument-Bromage H., Tempst P., Conaway J.W., Conaway R.C., Kornberg R.D. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc. Natl. Acad. Sci. USA 1998, 95:8538-8543.
35. Kieffer-Kwon K.R., Tang Z., Mathe E., Qian J., Sung M.H., Li G., Resch W., Baek S., Pruett N., Grøntved L., et al. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell 2013, 155:1507-1520.
36. Kruidenier L., Chung C.W., Cheng Z., Liddle J., Che K., Joberty G., Bantscheff M., Bountra C., Bridges A., Diallo H., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488:404-408.
37. Kwak H., Lis J.T. Control of transcriptional elongation. Annu. Rev. Genet. 2013, 47:483-508.
38. Lamonica J.M., Vakoc C.R., Blobel G.A. Acetylation of GATA-1 is required for chromatin occupancy. Blood 2006, 108:3736-3738.
39. Lamonica J.M., Deng W., Kadauke S., Campbell A.E., Gamsjaeger R., Wang H., Cheng Y., Billin A.N., Hardison R.C., Mackay J.P., Blobel G.A. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc. Natl. Acad. Sci. USA 2011, 108:E159-E168.
40. Li Q., Harju S., Peterson K.R. Locus control regions: coming of age at a decade plus. Trends Genet. 1999, 15:403-408.
41. Li Z., Guo J., Wu Y., Zhou Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 2013, 41:277-287.
42. Liu W., Ma Q., Wong K., Li W., Ohgi K., Zhang J., Aggarwal A.K., Rosenfeld M.G. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 2013, 155:1581-1595.
43. Lockwood W.W., Zejnullahu K., Bradner J.E., Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc. Natl. Acad. Sci. USA 2012, 109:19408-19413.
44. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
45. Matzuk M.M., McKeown M.R., Filippakopoulos P., Li Q., Ma L., Agno J.E., Lemieux M.E., Picaud S., Yu R.N., Qi J., et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012, 150:673-684.
46. Mele D.A., Salmeron A., Ghosh S., Huang H.R., Bryant B.M., Lora J.M. BET bromodomain inhibition suppresses TH17-mediated pathology. J.Exp. Med. 2013, 210:2181-2190.
47. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Bergeron L., Sims R.J. Targeting MYC dependence incancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 2011, 108:16669-16674.
48. Roy S., Ernst J., Kharchenko P.V., Kheradpour P., Negre N., Eaton M.L., Landolin J.M., Bristow C.A., Ma L., et al. Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science 2010, 330:1787-1797. modENCODE Consortium.
49. Morinière J., Rousseaux S., Steuerwald U., Soler-López M., Curtet S., Vitte A.L., Govin J., Gaucher J., Sadoul K., Hart D.J., et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 2009, 461:664-668.
50. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.W., Chandwani R., Marazzi I., Wilson P., Coste H., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
51. Parker S.C., Stitzel M.L., Taylor D.L., Orozco J.M., Erdos M.R., Akiyama J.A., van Bueren K.L., Chines P.S., Narisu N., Black B.L., et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc. Natl. Acad. Sci. USA 2013, 110:17921-17926. NISC Comparative Sequencing Program, National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program AuthorsNational Institutes of Health Intramural Sequencing Center Comparative Sequencing Program Authors, NISC Comparative Sequencing Program AuthorsNISC Comparative Sequencing Program Authors.
52. Patel M.C., Debrosse M., Smith M., Dey A., Huynh W., Sarai N., Heightman T.D., Tamura T., Ozato K. BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes. Mol. Cell. Biol. 2013, 33:2497-2507.
53. Picaud S., Wells C., Felletar I., Brotherton D., Martin S., Savitsky P., Diez-Dacal B., Philpott M., Bountra C., Lingard H., et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. USA 2013, 110:19754-19759.
54. Prinjha R.K., Witherington J., Lee K. Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol. Sci. 2012, 33:146-153.
55. Puissant A., Frumm S.M., Alexe G., Bassil C.F., Qi J., Chanthery Y.H., Nekritz E.A., Zeid R., Gustafson W.C., Greninger P., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Dis. 2013, 3:308-323.
56. Rahman S., Sowa M.E., Ottinger M., Smith J.A., Shi Y., Harper J.W., Howley P.M. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol. Cell. Biol. 2011, 31:2641-2652.
57. Schröder S., Cho S., Zeng L., Zhang Q., Kaehlcke K., Mak L., Lau J., Bisgrove D., Schnölzer M., Verdin E., et al. Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J.Biol. Chem. 2012, 287:1090-1099.
58. Shi J., Whyte W.A., Zepeda-Mendoza C.J., Milazzo J.P., Shen C., Roe J.S., Minder J.L., Mercan F., Wang E., Eckersley-Maslin M.A., et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 2013, 27:2648-2662.
59. Shi J., Wang Y., Zeng L., Wu Y., Deng J., Zhang Q., Lin Y., Li J., Kang T., Tao M., et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 2014, 25:210-225.
60. Spiltoir J.I., Stratton M.S., Cavasin M.A., Demos-Davies K., Reid B.G., Qi J., Bradner J.E., McKinsey T.A. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J.Mol. Cell. Cardiol. 2013, 63:175-179.
61. Wang F., Liu H., Blanton W.P., Belkina A., Lebrasseur N.K., Denis G.V. Brd2 disruption in mice causes severe obesity without Type 2 diabetes. Biochem. J. 2010, 425:71-83.
62. Weidner-Glunde M., Ottinger M., Schulz T.F. WHAT do viruses BET on?. Front Biosci (Landmark Ed) 2010, 15:537-549.
63. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., Rahl P.B., Lee T.I., Young R.A. Master transcription factors andmediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
64. Wu S.Y., Chiang C.M. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J.Biol. Chem. 2007, 282:13141-13145.
65. Wu S.Y., Lee A.Y., Hou S.Y., Kemper J.K., Erdjument-Bromage H., Tempst P., Chiang C.M. Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Dev. 2006, 20:2383-2396.
66. Wu S.Y., Lee A.Y., Lai H.T., Zhang H., Chiang C.M. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 2013, 49:843-857.
67. Yan J., Enge M., Whitington T., Dave K., Liu J., Sur I., Schmierer B., Jolma A., Kivioja T., Taipale M., Taipale J. Transcription factor binding inhuman cells occurs in dense clusters formed around cohesin anchor sites. Cell 2013, 154:801-813.
68. Yang Z., Yik J.H., Chen R., He N., Jang M.K., Ozato K., Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 2005, 19:535-545.
69. Yang Z., He N., Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 2008, 28:967-976.
70. You J., Croyle J.L., Nishimura A., Ozato K., Howley P.M. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004, 117:349-360.
71. Zhang W., Prakash C., Sum C., Gong Y., Li Y., Kwok J.J., Thiessen N., Pettersson S., Jones S.J., Knapp S., et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ Tcells. J.Biol. Chem. 2012, 287:43137-43155.
72. Zhao Q., Rank G., Tan Y.T., Li H., Moritz R.L., Simpson R.J., Cerruti L., Curtis D.J., Patel D.J., Allis C.D., et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 2009, 16:304-311.
73. Zhao R., Nakamura T., Fu Y., Lazar Z., Spector D.L. Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation. Nat. Cell Biol. 2011, 13:1295-1304.
74. Zhou Q., Li T., Price D.H. RNA polymerase II elongation control. Annu. Rev. Biochem. 2012, 81:119-143.
75. Zhu J., Gaiha G.D., John S.P., Pertel T., Chin C.R., Gao G., Qu H., Walker B.D., Elledge S.J., Brass A.L. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep. 2012, 2:807-816.
76. Zippo A., Serafini R., Rocchigiani M., Pennacchini S., Krepelova A., Oliviero S. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 2009, 138:1122-1136.
77. Zou Z., Huang B., Wu X., Zhang H., Qi J., Bradner J., Nair S., Chen L.F. Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA. Oncogene 2013, 33:2395-2404.
78. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.